We are live on ! Find out more
VOR icon

Vor Biopharma
VOR

71 hedge funds and large institutions have $54.5M invested in Vor Biopharma in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

4% more funds holding

Funds holding: 68 → 71 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.33% less ownership

Funds ownership: 4.32% → 3.99% (-0.33%)

11% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 19

61% less capital invested

Capital invested by funds: $140M → $54.5M (-$85.2M)

Holders
71
Holders Change
+3
Holders Change %
+4.41%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
23
Increased
17
Reduced
19
Closed
20
Calls
$16K
Puts
–
Net Calls
+$16K
Net Calls Change
-$21K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$456K
2
Millennium Management
Millennium Management
New York
+$374K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$357K
4
Jane Street
Jane Street
New York
+$328K
5
Renaissance Technologies
Renaissance Technologies
New York
+$260K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.83M
2
WP
Woodline Partners
California
-$2.63M
3
AG
Artal Group
Luxembourg
-$2.37M
4
LCM
Laurion Capital Management
New York
-$1.06M
5
State Street
State Street
Massachusetts
-$876K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$22.7M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$7.08M -$861K -26,632 -7%
PBA
3
Paradigm Biocapital Advisors
New York
$6.46M – – –
5VM
4
5AM Venture Management
California
$6.36M – – –
LCM
5
Laurion Capital Management
New York
$2.53M -$1.06M -32,872 -21%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.95M +$229K +7,069 +8%
JJ
7
Johnson & Johnson
New Jersey
$1.07M – – –
SCM
8
Sarissa Capital Management
Connecticut
$618K – – –
BlackRock
9
BlackRock
New York
$498K -$2.83M -87,488 -78%
Renaissance Technologies
10
Renaissance Technologies
New York
$495K +$260K +8,032 +48%
MCM
11
MAI Capital Management
Ohio
$470K +$169K +5,210 +28%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$425K -$673K -20,818 -49%
Millennium Management
13
Millennium Management
New York
$390K +$374K +11,562 +146%
Northern Trust
14
Northern Trust
Illinois
$381K -$28.5K -881 -4%
Goldman Sachs
15
Goldman Sachs
New York
$375K +$456K +14,108 +303%
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$346K – – –
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$247K +$357K +11,029 +830%
Jane Street
18
Jane Street
New York
$223K +$328K +10,150 +1,041%
Morgan Stanley
19
Morgan Stanley
New York
$169K +$68.9K +2,130 +34%
BCM
20
Bridgeway Capital Management
Texas
$166K +$53.7K +1,660 +25%
YIH
21
Y-Intercept (HK)
Hong Kong
$132K +$214K +6,615 New
ETC
22
Exchange Traded Concepts
Oklahoma
$118K -$59.3K -1,833 -24%
State Street
23
State Street
Massachusetts
$116K -$876K -27,088 -82%
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$95.4K +$154K +4,768 New
Citadel Advisors
25
Citadel Advisors
Florida
$84.6K +$64K +1,978 +88%
1
2 3 4

VOR Hedge Fund Activity: Q2 2024 in Review

71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2024, worth a combined $54.5M — down 61% from $140M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new VOR positions and 20 closed out — a net gain of 3 holders — while 17 added to existing stakes and 19 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $456K. The largest seller was BlackRock, cutting an estimated $2.83M.

  • 71 institutional investors held Vor Biopharma (VOR) as of Q2 2024, up from 68 in Q1 2024.
  • Funds reported $54.5M of Vor Biopharma stock for Q2 2024, down 61% quarter-over-quarter.
  • 23 funds opened new Vor Biopharma positions in Q2 2024 and 20 closed out, a net change of +3 holders.
  • The largest Vor Biopharma buyer in Q2 2024 was Goldman Sachs, an estimated $456K added.
  • The largest Vor Biopharma seller in Q2 2024 was BlackRock, an estimated $2.83M sold.

Based on aggregated 13F filings for Q2 2024.